19 June 2013
Keywords: novacea, stops, ph, iii, asentar, trial, usa-based
Article | 12 November 2007
USA-based biopharmaceutical firm Novacea has stopped a Phase III trial of its prostate cancer therapy Asentar (DN-101), co-developed with
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 November 2007
5 November 2007
19 November 2007
© 2013 thepharmaletter.com